Modular Finance IR Consensus: XVIVO Perfusion – Consensus estimates Q2 2024
Estimates compiled by Modular Finance on behalf of XVIVO Perfusion.
Number of contributors: 6 (all of which have been updated or confirmed before the report)
| KPI (MSEK, unless otherwise specified) | Q2 2024E |
| Net sales | 192 |
| Organic growth in local currency (%) | 22.2 |
| Gross profit | 141 |
| EBITDA | 36 |
| EBIT | 18 |
| Net profit | 16 |
| Earnings per share (SEK) | 0.52 |
| Net sales per segment: | |
| Thoracic | 125 |
| Abdominal | 45 |
| Services | 22 |
XVIVO Perfusion’s Q2 report will be released on Friday, 12 July, at 07:30 a.m. CEST.